close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AAVantgarde

News headline image
AAVantgarde to present progress toward the first treatment for Usher syndrome type 1B at EYENOVATE and FLORetina 2026
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde to Showcase Clinical Progress in Usher 1B and Stargardt Disease at EURetina 2026
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Announces Participation of Founder and CSO, Prof. Alberto Auricchio at the 32nd Annual Meeting of the Japanese Society for Gene and Cell Therapy
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde announces completion of recruitment in STELLA natural history study
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde appoints Philip Lao as Senior Vice President of Business Development
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer
From AAVantgarde
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.